SK Bioscience Signs Advance Purchase Agreement for Domestic Vaccine Supply Worth 200 Billion KRW...
SK Bioscience 'L House Vaccine Center' in Andong-si, Gyeongbuk (Photo by SK Bioscience)
View original image[Asia Economy Reporter Chunhee Lee] SK Bioscience announced on the 21st that it has signed a pre-purchase supply contract with the government for the domestically developed COVID-19 vaccine 'GBP510'. The contract amount is 200 billion KRW.
Previously, the government had announced plans to promote the pre-purchase of up to 10 million doses of the domestically developed COVID-19 vaccine by SK Bioscience to support domestic vaccine development.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
However, SK Bioscience also stated that if domestic approval is not obtained by the end of this year or within an extended period mutually agreed upon by the contracting parties, the contract may be terminated. Currently, SK Bioscience is conducting a global Phase 3 clinical trial of GBP510 involving 3,990 participants. The plan is to obtain domestic approval within the first half of this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
